MorphoSys AG
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid t… Read more
MorphoSys AG (MPSYF) - Total Assets
Latest total assets as of March 2024: $1.83 Billion USD
Based on the latest financial reports, MorphoSys AG (MPSYF) holds total assets worth $1.83 Billion USD as of March 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
MorphoSys AG - Total Assets Trend (2002–2023)
This chart illustrates how MorphoSys AG’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
MorphoSys AG - Asset Composition Analysis
Current Asset Composition (December 2023)
MorphoSys AG's total assets of $1.83 Billion consist of 40.2% current assets and 59.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.8% |
| Accounts Receivable | $42.65 Million | 2.1% |
| Inventory | $62.07 Million | 3.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $844.11 Million | 41.7% |
| Goodwill | $342.30 Million | 16.9% |
Asset Composition Trend (2002–2023)
This chart illustrates how MorphoSys AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MorphoSys AG's current assets represent 40.2% of total assets in 2023, a decrease from 69.7% in 2002.
- Cash Position: Cash and equivalents constituted 7.8% of total assets in 2023, up from 2.0% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 57.0% of total assets, an increase from 24.0% in 2002.
- Asset Diversification: The largest asset category is intangible assets at 41.7% of total assets.
MorphoSys AG Competitors by Total Assets
Key competitors of MorphoSys AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
MorphoSys AG - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - MorphoSys AG generates 0.12x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - MorphoSys AG is currently not profitable relative to its asset base.
MorphoSys AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.38 | 3.57 | 7.61 |
| Quick Ratio | 1.38 | 3.27 | 7.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $187.17 Million | $ 621.17 Million | $ 342.25 Million |
MorphoSys AG - Advanced Valuation Insights
This section examines the relationship between MorphoSys AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 51.54 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -15.5% |
| Total Assets | $2.03 Billion |
| Market Capitalization | $16.92 Million USD |
Valuation Analysis
Below Book Valuation: The market values MorphoSys AG's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: MorphoSys AG's assets decreased by 15.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for MorphoSys AG (2002–2023)
The table below shows the annual total assets of MorphoSys AG from 2002 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $2.03 Billion | -15.46% |
| 2022-12-31 | $2.40 Billion | -6.23% |
| 2021-12-31 | $2.56 Billion | +54.04% |
| 2020-12-31 | $1.66 Billion | +234.28% |
| 2019-12-31 | $496.44 Million | -7.86% |
| 2018-12-31 | $538.76 Million | +29.70% |
| 2017-12-31 | $415.40 Million | -10.40% |
| 2016-12-31 | $463.60 Million | +15.88% |
| 2015-12-31 | $400.08 Million | -6.19% |
| 2014-12-31 | $426.48 Million | -4.73% |
| 2013-12-31 | $447.66 Million | +99.59% |
| 2012-12-31 | $224.29 Million | -1.80% |
| 2011-12-31 | $228.41 Million | +7.46% |
| 2010-12-31 | $212.55 Million | +3.14% |
| 2009-12-31 | $206.09 Million | +1.38% |
| 2008-12-31 | $203.29 Million | +10.06% |
| 2007-12-31 | $184.71 Million | +44.48% |
| 2006-12-31 | $127.84 Million | +59.57% |
| 2005-12-31 | $80.12 Million | +43.59% |
| 2004-12-31 | $55.80 Million | +21.93% |
| 2003-12-31 | $45.76 Million | +7.94% |
| 2002-12-31 | $42.39 Million | -- |